Sarepta Therapeutics Inc (SRPT)
115.62
-0.93
(-0.80%)
USD |
NASDAQ |
Apr 19, 16:00
117.00
+1.38
(+1.19%)
After-Hours: 20:00
Sarepta Therapeutics Enterprise Value: 10.41B for April 19, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 19, 2024 | 10.41B |
| April 18, 2024 | 10.50B |
| April 17, 2024 | 10.63B |
| April 16, 2024 | 10.57B |
| April 15, 2024 | 10.67B |
| April 12, 2024 | 11.09B |
| April 11, 2024 | 11.24B |
| April 10, 2024 | 11.42B |
| April 09, 2024 | 11.48B |
| April 08, 2024 | 11.42B |
| April 05, 2024 | 11.40B |
| April 04, 2024 | 11.37B |
| April 03, 2024 | 11.47B |
| April 02, 2024 | 11.48B |
| April 01, 2024 | 11.61B |
| March 28, 2024 | 11.71B |
| March 27, 2024 | 11.78B |
| March 26, 2024 | 11.60B |
| March 25, 2024 | 11.57B |
| March 22, 2024 | 11.53B |
| March 21, 2024 | 11.29B |
| March 20, 2024 | 11.40B |
| March 19, 2024 | 11.21B |
| March 18, 2024 | 11.20B |
| March 15, 2024 | 11.11B |
| Date | Value |
|---|---|
| March 14, 2024 | 11.18B |
| March 13, 2024 | 11.01B |
| March 12, 2024 | 11.01B |
| March 11, 2024 | 10.97B |
| March 08, 2024 | 11.23B |
| March 07, 2024 | 10.90B |
| March 06, 2024 | 10.85B |
| March 05, 2024 | 11.09B |
| March 04, 2024 | 11.19B |
| March 01, 2024 | 11.64B |
| February 29, 2024 | 11.57B |
| February 28, 2024 | 12.47B |
| February 27, 2024 | 12.85B |
| February 26, 2024 | 12.48B |
| February 23, 2024 | 12.38B |
| February 22, 2024 | 12.19B |
| February 21, 2024 | 11.96B |
| February 20, 2024 | 12.32B |
| February 16, 2024 | 12.18B |
| February 15, 2024 | 11.27B |
| February 14, 2024 | 11.21B |
| February 13, 2024 | 11.20B |
| February 12, 2024 | 11.50B |
| February 09, 2024 | 11.45B |
| February 08, 2024 | 11.50B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
4.483B
Minimum
Jan 19 2022
13.99B
Maximum
May 15 2023
8.366B
Average
8.580B
Median
Jan 02 2024
Enterprise Value Benchmarks
| PTC Therapeutics Inc | 3.161B |
| Vertex Pharmaceuticals Inc | 90.68B |
| Regenxbio Inc | 493.44M |
| CytomX Therapeutics Inc | -61.41M |
| Apellis Pharmaceuticals Inc | 5.474B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 45.66M |
| Revenue (Quarterly) | 396.78M |
| Total Expenses (Quarterly) | 372.16M |
| EPS Diluted (Quarterly) | 0.76 |
| Gross Profit Margin (Quarterly) | 88.87% |
| Profit Margin (Quarterly) | 11.51% |
| Earnings Yield | -5.04% |
| Normalized Earnings Yield | -1.804 |